The Latest Breaking News from Recursion Pharmaceuticals

These smaller stocks may carry more risk, but they also carry greater reward potential.

Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

These under-the-radar companies may offer greater long-term rewards.

You're doing something right if your company is worth $2.6 trillion like Nvidia. And it's worth looking at the companies Nvidia invests in.

Morgan Stanley is betting on these stocks to benefit from the AI megatrend.

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.